A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage

被引：0
|
作者：
Zhou, Jian
Fan, Jia
Gu, Fang-Ming
Li, Tao
Bai, Dou-Sheng
Sun, Hui-Chuan
Wang, Zheng
Qiu, Shuang-Jian
Ye, Qing-Hai
Shi, Ying-Hong
Gao, Qiang
Wang, Xiao-Ying
Yang, Xin-Rong
Shi, Guo-Ming
Peng, Yuan-Fei
机构：
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Minist Educ, Shanghai, Peoples R China
[2] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China
[3] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Yangzhou Univ, Subei Peoples Hosp, Yangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4126
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial.
    Zhao Hong
    Zhao Jianjun
    Jiang Li
    Bi Xinyu
    Qian Honggang
    Du Shunda
    Cai Jianqiang
    Zhou Jianguo
    Li Zhiyu
    Liu Dongbin
    Zhang Yubao
    Zhang Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] A combined modality treatment with primary chemotherapy followed by Transoral Laser Microsurgery in intermediate stage laryngeal squamous cell carcinoma: A phase II study
    Rocca, M. Cossu
    Chiocca, S.
    Maffini, F.
    Santoro, L.
    Cattaneo, A.
    Alterio, D.
    Verri, E.
    DeBenedetto, L.
    Massaro, M.
    Iacovelli, R.
    Preda, L.
    Cullura, D.
    Tagliabue, M.
    Aurilio, G.
    Lepanto, D.
    Nole, F.
    Ansarin, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S568 - S568
  • [33] Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING)
    Tan, Li
    Xu, Lixia
    Shen, Shun-Li
    Li, Dongming
    Hua, Yunpeng
    Li, Shaoqiang
    Liang, Lijian
    He, Qiang
    Zhou, Qi
    Xie, Wenxuan
    Chen, Zebin
    Wu, Jian
    Li, Jiaping
    Fan, Wenzhe
    Zhuang, Wenquan
    Chen, Lili
    Feng, Shiting
    Peng, Sui
    Wang, Jiping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).
    Zhao, Zerui
    Chen, Si
    Qi, Han
    Yang, Chao-Pin
    Lin, Yao-Bin
    Jin, Jie-Tian
    Lian, Shan-Shan
    Wang, Yi-Zhi
    Yu, Hui
    Hao, Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
    De Velasco Oria, G. A.
    Garralda, E.
    Bernabe Caro, R.
    Brana, I.
    Pons, S.
    Garrido, E.
    Galan Servan, R.
    Paz-Ares, L. G.
    ANNALS OF ONCOLOGY, 2024, 35 : S306 - S307
  • [36] Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
    Ueshima, Kazuomi
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Kato, Naoya
    Yamashita, Tatsuya
    Shimose, Shigeo
    Numata, Kazushi
    Kodama, Yuzo
    Tanaka, Yasuhito
    Kuroda, Hidekatsu
    Itoh, Shinji
    Aikata, Hiroshi
    Hiraoka, Atsushi
    Moriguchi, Michihisa
    Wada, Yoshiyuki
    Nakao, Kazuhiko
    Tateishi, Ryosuke
    Ogasawara, Sadahisa
    Yamamoto, Kouji
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma
    Abou Alfa, G. K.
    Johnson, P.
    Knox, J.
    Lacava, J.
    Leung, T.
    Mori, A.
    Leberre, M. A.
    Voliotis, D.
    Saltz, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 259
  • [38] Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
    Lorenzen, Sylvie
    Goetze, Thorsten Oliver
    Thuss-Patience, Peter
    Biebl, Matthias
    Homann, Nils
    Schenk, Michael
    Lindig, Udo
    Heuer, Vera
    Kretzschmar, Albrecht
    Goekkurt, Eray
    Haag, Georg Martin
    Riera-Knorrenschild, Jorge
    Bolling, Claus
    Hofheinz, Ralf-Dieter
    Zhan, Tianzuo
    Angermeier, Stefan
    Ettrich, Thomas Jens
    Siebenhuener, Alexander Reinhard
    Elshafei, Moustafa
    Bechstein, Wolf Otto
    Gaiser, Timo
    Loose, Maria
    Sookthai, Disorn
    Kopp, Christina
    Pauligk, Claudia
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 410 - 420
  • [39] ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Zheng, Jinfang
    Fu, Changbo
    Xu, Guohui
    Bai, Yannan
    Wu, Changxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS632 - TPS632
  • [40] Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results
    Reddy, Nishitha M.
    Morgan, David S.
    Greer, John P.
    Chen, Heidi
    Park, Steven I.
    Richards, Kristy L.
    BLOOD, 2015, 126 (23)
12345